ANTIHISTAMINIC AGENTS / Pharmacology notes / What is Histamine / KDT Notes / B.Pharma Notes / satta and king

 ANTIHISTAMINIC AGENTS

1.1.1. Introduction Histamine, a biologically active substance potentiates the inflammatory and immune responses of the body. It also regulates the physiological functions in the gut, and behaves as neurotransmitter. Anti-histaminic agents (or histamine antagonists) are the drugs that antagonise the action of histamine. On the basis of the type of H receptor targeted, antihistamines are divided into: 

1) H1-Antihistamines: They are used for treating allergic reactions and disorders mediated by mast cells. H1-antihistamines are subdivided into two generations. The first generation H1-antihistamines have a central effect so are used as sedatives. The second generation H1- antihistamines have low central effects so are used as anti-allergenic drugs. 

2) H2-Antihistamines: They can reduce the production of stomach acid by reversibly blocking the H2-histamine receptors found in the parietal cells of gastric mucosa; thus, they are used in gastric reflux diseases.

 The pregnant women and children should avoid using most H1- and H2- antihistamines. First-generation H1-antihistamines are contraindicated in patients having angle-closure glaucoma and pyloric stenosis.

 1.1.2. Histamine


 Histamines are nitrogen containing organic compounds belonging to the group of amines. Histamines are produced in almost all the cells (present in an animal) during a local immune response. They regulate various physiological functions of the gut. In addition, histamines have also be en known to play a role in neurotransmission. Release of histamines is the initiating factor of any inflammatory response. 

Histamines are synthesised and released by basophils and mast cells (found in the nearby connective tissues) on stimulation (as a part of an immune response against foreign pathogens). They cause increased vascular (capillary) permeability for WBCs and other proteins to facilitate adequate invasion of foreign bodies within the tissues. 

1.1.3. Histamine Receptors and their Distribution in the Human Body 

The biological effects produced by histamine are mediated through histaminergic receptors (H1, H2 and H3 types). Histamine was identified and anti-histamines (H1 blockers) were synthesised in the beginning of this century. Since then i t was known that these anti-histamines cannot block all the histamine actions. H4 receptors are linked to the pathology of allergy and asthma; and regulate the changes in cellular shape, chemotaxis, and up -regulation of adhesi on molecules (CD11b/CD18 and ICAM, P -selectin). H 4-receptors present on haematopoietic cells (neutrophils and eosinophils) have been recognised lately.

1.1.4. Classification of Antihistaminic Agents Following are the three types of histamine receptor antagonists: 1) H1-Antagonists: These are classical antihistamines blocking the physiological effects of histamine and used in allergic disorders.

2) H2-Antagonists: Cimetidine, Ranitidine, and Famotidine are H 2-antagonists reducing gastric HCl secretion and used in peptic ulcer diseases.

 3) H3-Antagonists: Thioperamide is an H 3-antagonist regulating histamine release from histaminergic neurons of CNS by presynap tic auto -regulatory mechanism. It is not recommended to be used therapeutically. 

1.1.5. Mechanism of Action 

Histamine binds with the histaminergic receptors (H 1, H 2, and H 3) after being released by the mast cells. This binding stimulates a series of events that facilitate the characteristic responses by second messenger systems. The histaminergic receptors are G -protein coupled type. Thus, the H1-receptors are coupled to phospholipase-C and on activation they form inositol phosphate (Ip 3) and diacylglycerol (DAG) from the cell membrane phospholipids. Ca2+ ions are rapidly released from endoplasmic reticulum under the influence of Ip3.

 Protein kinase C is activated by DAG. Thus, the turnover of Ca 2+ ions and protein kinase C stimulates the Ca2+/calmodulin dependent protein kinase and phospholipase A 2. The anti -histaminergic (H 1-antagonist) binds to the H 1- receptors and decreases the production of phospholipase-C and their activation to form IP3 and DAG. Therefore, it inhibits the characteristic response of histamine. Histamine forms cAMP-dependent protein kinase (also known as cyclic AMP or 3-5-cyclic adenosine monophosphate) on H2-receptors for producing a response in the GIT. The H 2-antagonist and the H 2-receptors bind reversibly and this decreases cAMP formation. Subsequently, the proton pump is activated and the formation of gastric acid in the GIT decreases. H3-receptors are a lso G-protein coupled receptors .

 They decrease the Ca2+ ions influx. H 3-receptors act as feedback inhibitors for histamine a nd other neurotransmitters as they reduce calcium influx in the cells in CNS, decrease gastrin secretion in the GIT, and down-stimulates histamine by auto-regulatory effects. These effects are antagonised by blocking the H3-receptors, whereas the clinical extendibility is narrow for H3. 1.1.6. Uses Following are the therapeutic uses of antihistaminic agents: 

1) They have same efficacy when used in suitable doses. 
2) The H2-blockers are used for reducing gastric acid secretion. 
3) Sometimes other types of therapy are similarly effective, still the H2-blockers are chosen due to suitability and good patient acceptability.

1.1.7. Structure-Activity Relationship H1-Receptor Antagonists

1) Aryl Groups: Diaryl substitution is required for H 1 affinity, and is found in first-generation and second -generation antihistamines. The co -planarity of two aryl substitutions influences the optimal antihistaminic activity. Active aryl substitutions are as follows: i) Ar is phenyl and hetero aryl group (like 2-pyridyl). ii) Ar1 is aryl or aryl methyl group.


2) Nature of X: Antihistamines with X = carbon (pheniramine series ) signifies the stereo selective receptor binding to the receptors because of its chirality. The active substitutions of X are as follows: i) X = Oxygen (amino alkyl ether analogue) ii) X = Nitrogen (ethylene-diamine derivative) iii) X = Carbon (mono amino propyl analogue) 3) Alkyl Chain: Mostly antihistamines have ethylene chain, t he b ranching of which forms a less active compound.
This general chain is present in all the antihistamines. 4) Terminal Nitrogen Atom: The nitrogen atom at the terminal should be a tertiary amine for maximum activity. The terminal nitrogen can be the part of heterocyclic ring, for example , antazoline and chlorcyclizine have a high antihistaminic activity. The am ino moiety on interaction with H 1-receptor shows protonation due to basicity with pka 8.5-10.


H2-Receptor Antagonists H2-blockers are not like H 1-blockers that are typically lipophilic amines. Instead, they are very polar in nature ( e.g., cimetidine). H 2-blockers also have longer uncharged side chains non -related to the protonated dialkylaminoalkyl side chains present in H 1-blockers. The imidazole ring in H 2-blocker structure is important for the identification of the receptor.


1) Imidazole Ring Substitutions : The imidazole ring is found in two tautomeric forms as shown below. The first form (I) is important for maximal H2-antagonistic activity. Mostly, the activity is potentiated when R is a –CH3 group


2) Chain: Four carbon atoms chain is best for the activity of H2-blockers. The antagonist activity is extremely reduced in case of a shorter chain. The chain should have an electron withdrawing substituent. An isosteric thioether (─S─) link at the place of methylene group (─CH2─) gives more active compounds. 3) Terminal Nitrogen Group: To achieve maximal antagonist activity t he terminal N -group should be a polar, non -basic substituent. A positively charged group binds more firmly to the receptor and this exerts an agonist activity (and not an antagonist activity).


 1.1.8. Recent Developments The effect of first generation sedating H 1-antihistamines i n humans has never been investigated. But, most of the second -generation non -sedating H 1- antihistamines are well investigated. The H1-antihistamines are widely used in the treatment of allergic rhinitis, allergic conjunctivitis, and chronic urticaria. The second generation H1-antihistamines produce comparatively less CNS and cardiac toxicity if taken in standard doses and even in overdose. Screening and structural modification of the pre -existing second generation H1 antihistamines have led to the identification of many new medications of the same class. For example, cetirizine is a metabolite of hydroxyzine, levocetirizine is the active R -enantiomer of cetirizine, desloratadine is a metabolite of loratadine, and fexofenadine is a metabolite of terfenadine. New H1-antihistamines continue to be developed and introduced for clinical use; however, they should be inspected carefully as they may or may n ot exhibit clinically important features as compared to the existing second generation H1- antihistamines. Till date, no second generation H1-antihistamine is found to have efficacy superior to the others, though some are safer. The terms third generation, new generation, or next generation are used to market certain new H 1-antihistamines. But, clinically advantageous H 1- antihistamines should be designated by these terms. Some of these medications also have the intrinsic ab ility to down -regulate histamine a t H 2-, H 3-, or H 4- receptors or to down-regulate leukotrienes or cytokines. Without the discussion of histamine -globulin injection , any discussion on histamine is incomplete. There are no double-blind placebo-controlled, published studies on this formulati on, however , it is generally prescribed in India. This combination should be banned 


1.2. H1-ANTAGONISTS

1.2.1. Introduction Until the discovery of H 1-receptors, no other histamine receptors had been identified. The H1-antagonists, termed as antihistamines cause a co mpetitive inhibition of only H1-receptors (they do not block any other histamine receptors). Adrenaline is a physio logical antagonist of histamine. It acts via adrenergic receptors and reverses the bronchodila tion and vasoconstriction effects of histamine. Cromolyn sodium and corticosteroids block h istamine release from mast cells. The H1-receptor antagonists are employed in the treatment of allergic disorders. The action of histamines on H 1-receptors is blocked by antihistamines (H 1- blockers) categorised into first and second generations. The first generation antihistamines bind to the central and peripheral H 1-receptors, while the second generation antihistamines bind to the peripheral H1-receptors. Though the sedative effects of second generation antih istamines are lesser as compared to the first generation antihistamines, still they are beneficial for the treatment of allergies. 
1.2.2. Study of Individual Drugs The following H1-antagonists are discussed below:
 1) Diphenhydramine hydrochloride, 
2) Dimenhydrinate,
 3) Doxylamine succinate,
 4) Clemastine fumarate, 
5) Diphenylpyraline hydrochloride,
6) Tripelennamine hydrochloride, 
7) Chlorcyclizine hydrochloride, 
8) Meclizine hydrochloride, 
9) Buclizine hydrochloride, 
10) Chlorpheniramine maleate,
 11) Triprolidine hydrochloride, 
12) Phenindamine tartrate, 
13) Promethazine hydrochloride,
 14) Trimeprazine tartrate,
 15) Cyproheptadine hydrochloride, 
16) Azatadine maleate, 
17) Astemizole,
 18) Loratadine,
 19) Cetirizine,
 20) Levocetirizine, and 
21) Cromolyn sodium. 

1.2.2.1. Diphenhydramine Hydrochloride Diphenhydramine is a first generation antihistamine which is mainly used for treating seasonal allergies. But it also exhibits antiemetic, anti -Parkinson, antitussive, and hypnotic properties.
Synthesis Firstly, diphenylmethane undergoes bromination in the presence of light to form diphenylbromomethane. Then, diphenylbromomethane, -dimethyl-aminoethanol, and sodium carbonate are heated in the presence of toluene to obtain diphenhydramine base. The purified diphenhydramine after distilling-off toluene converts into its hydrochloride form with hydrogen chloride.

Mechanism of Action Diphenhydramine works through the antagonism of H 1-receptors found on the respiratory smooth muscles, vascular endothelial cells, GIT, cardiac tissue, immune cells, uterus, and CNS neurons. On stimulating the H1-receptors in these tissues, they increase vascular permeability, stimulate vasodilation that leads to flushing, decrease the conduction time of atrioventricular (AV) node , stimulate the sensory nerves of a irways that leads to coughing, contract the smooth muscles of bronchi and GIT, and cause eosinophilic chemotaxis that enhances the allergic immune response. Diphenhydramine functions as an inverse agonist at H1-receptors, and then it converses the histamine effects on capillaries, and decreases the symptoms of allergic reaction 

No comments

Powered by Blogger.